Collaboration will develop phenotypic personalized medicine platform for cancer patients

June 27, 2016
IntelliCyt and Notable Labs will further the development of a predictive personalized medicine platform for cancer patients.

IntelliCyt (Albuquerque, NM), which develops integrated platforms that accelerate drug discovery, antibody discovery, and immuno-oncology research, is collaborating with Notable Labs (San Francisco, CA) to further the development of a predictive personalized medicine platform. The two companies recognize that next-generation platforms must integrate immune profiling in physiologically relevant ex vivo microenvironments (cancer patient cells, in this case) to ensure clinical translation of laboratory results.

Related: Fluorescing engineered DNA promises personalized cancer therapy

Notable Labs helps oncologists identify effective therapies that they can prescribe by testing them on a patient's own cells. This approach promises tailored treatment options fast enough for doctors to put to use. By testing a broad set of drugs and drug combinations, the company is able to functionally profile cancer cells, which leads to a better understanding of the biological mechanisms of the patient's cancer. Providing this information to physicians can improve treatment outcomes while reducing side effects.

Notable Labs will use IntelliCyt's iQue Screener PLUS platform in a fully automated, high-throughput laboratory to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Prioritized treatment options will be highlighted in reports to clinicians using Notable Lab's screening process with IntelliCyt's immune-profiling technology.

The platform, which integrates an instrument, software and reagent system, offers a proprietary high-throughput sampling capability that enables the rapid assessment of cells and beads in suspension in 96-, 384-, and 1536-well plates. Miniaturization of the assay is possible to save reagent cost and conserve samples, and high-content, multiplex readouts are generated on each individual cell or bead via the flow cytometry-based detection system.

For more information, please visit www.intellicyt.com and www.notablelabs.com.

Sponsored Recommendations

Brain Computer Interface (BCI) electrode manufacturing

Jan. 31, 2025
Learn how an industry-leading Brain Computer Interface Electrode (BCI) manufacturer used precision laser micromachining to produce high-density neural microelectrode arrays.

Electro-Optic Sensor and System Performance Verification with Motion Systems

Jan. 31, 2025
To learn how to use motion control equipment for electro-optic sensor testing, click here to read our whitepaper!

How nanopositioning helped achieve fusion ignition

Jan. 31, 2025
In December 2022, the Lawrence Livermore National Laboratory's National Ignition Facility (NIF) achieved fusion ignition. Learn how Aerotech nanopositioning contributed to this...

Nanometer Scale Industrial Automation for Optical Device Manufacturing

Jan. 31, 2025
In optical device manufacturing, choosing automation technologies at the R&D level that are also suitable for production environments is critical to bringing new devices to market...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!